Pfizer says RSV shot to protect infants may be available by 2023-24 cold and flu season
Pfizer’s vaccine to protect infants from RSV may be approved before the next cold and flu season, the company said on Tuesday.
Regulators granted RSVpreF, also known as PF-06928316, a priority review for the prevention of medically attended lower respiratory tract illness (MA-LRTI) caused by RSV in infants. The shot would be administered during pregnancy to protect infants from birth to 6 months old.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.